A. Yes. Preliminary in-vitro work demonstrated that adding 2-methoxyestradiol produced significant additive antiproliferative effects with epirubicin and carboplatin at lower concentration ranges, indicating that the combination could allow dose reduction of these chemotherapeutics in ovarian cancer treatment [Mueck, 2004, PMID 15597845].